

## CoNCERT Pharmaceuticals Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 08-Feb-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 17

[Return to Table of Contents](#)

# CoNCERT Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	CoNCERT Pharmaceuticals Inc
Parent Company Name	CoNCERT Pharmaceuticals Inc
Website	<a href="http://www.concertpharma.com/">http://www.concertpharma.com/</a>
Country	US
Number of Drugs in Active Development	7
Number of Inactive Drugs	17
Number of Patents as Owner	162
Number of Patents as Third Party	1
Number of Deals	8
Key Indications	Neuropathic pain,Epilepsy,Inflammatory disease,Renal disease,Cancer,Pain,Multiple myeloma,Cystic fibrosis,Brain
Key Target-based Actions	NMDA receptor antagonist,GABA B receptor agonist,GABA A receptor modulator,CFTR stimulator,Calcium channel inhibitor T-type,Opioid receptor sigma agonist 1,HIV protease inhibitor,PDE inhibitor,Sigma opioid receptor agonist,Cytochrome P450 2D6 inhibitor,HIV-1 protease inhibitor
Key Technologies	Small molecule therapeutic,Oral formulation,Drug combination,Formulation preservation,Antibiotic,Capsule formulation,Controlled release formulation,Suspension,Crystalline form,Prodrug

## COMPANY PROFILE

### SUMMARY

CoNCERT Pharmaceuticals Inc is a Boston-based pharmaceutical company which uses chemical methodology, involving an innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, to create bioavailable drug candidates.

### EARLY R&D

By May 2009, Concert Pharmaceuticals was investigating deuterium analogs of rimonabant and mosapride.

By January 2008, the company was researching an HER2/EGFR inhibitor, an antiviral, a cytokine inhibitor and a number of antibiotics, for deuteration. By June 2008, CoNCERT was also researching a protease inhibitor for the potential treatment of HIV, an antifibrotic agent, an NMDA antagonist/ sigma agonist for the potential treatment of neuropathic pain, an antibacterial for the potential treatment of MRSA, an antipsychotic for the potential treatment for schizophrenia, a PDE-5 inhibitor for the potential treatment pulmonary arterial hypertension and benign prostate hyperplasia, a calcium modulator for the potential treatment of hyperparathyroidism, an EGFR inhibitor for the potential treatment of tumors and a CCR5 antagonist for the potential treatment of HIV.

### FINANCIAL

In December 2014, CoNCERT was selected for addition to the NASDAQ Biotechnology Index, effective from December 22, 2014.

In February 2014, CoNCERT priced a planned IPO of its common stock at \$14 per share. Underwriters would be granted a 30-day option to purchase up to an additional 900,000 shares at the same price to cover over-allotments. The shares would trade on the NASDAQ Global Market under the ticker symbol 'CNCE'. At that time, the offering was expected to close on February 19, 2014. Later that month, the offering was closed; in March 2014, underwriters exercised their over-allotment option and purchased an additional 649,690 shares which increased a capital raise of approximately \$93 million; at that time, net proceeds of \$83.1 million was raised.

In April 2008, CoNCERT Pharmaceuticals raised \$37 million in a series C financing round. The company planned to use the funds to advance its deuterium chemistry platform and product pipeline.

[Return to Table of Contents](#)



In November 2006, CoNCERT raised \$48.5 million in series B financing.

In July 2006, CoNCERT raised \$10 million from a series A venture capital financing.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	12.87
Change (USD)	-0.27 (-2.05%)
Previous Close Price (USD)	13.14
Volume	56,437
52-Week High (USD)	16.26
52-Week Low (USD)	7.12
Date	06-Feb-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	18,186,339
Current Market Capitalization	234,058,183
EPS (Date Reported)	-10.09442

[Return to Table of Contents](#)

STOCK PERFORMANCE




MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
iShares NASDAQ Biotechnology ETF	Mutual Fund	United States	215,868	1.19	3,190	0.01	31-Jan-2015
iShares Micro-Cap ETF	Mutual Fund	United States	18,946	0.1	-1,280	-0.06	31-Jan-2015

[Return to Table of Contents](#)



FINANCIAL PERFORMANCE



	2013	2011	2012		
Sales (USD M)	25.408	19.467	12.849		
Operating Income (USD M)	-4.71	-11.346	-18.61		
Net Income (USD M)	-6.056	-11.32	-20.444		

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	4.418	-7.608	-7.832
2014 Q2	1.235	-7.726	-7.99
2014 Q1	1.613	-6.519	-7.005
2013 Q4	1.413	-5.579	-6.015
2013 Q3	0.681	-7.116	-0.437
2013 Q2	17.441	9.415	0
2013 Q1	5.873	-1.13	-1.877
2012 Q4	0.223	-7.232	-7.857
2012 Q3	0.264	-8.333	-8.955

## BALANCE SHEET

### Assets (USD M)

	2011	2012	2013		
Cash & Short Term Investments	42.654	27.557	32.677		
Inventories - Total	0	0	0		
Current Assets - Total	44.135	28.85	34.045		
Property, Plant And Equipment - Net	4.438	3.454	2.473		
Other Assets - Total	0.124	0.119	2.549		
Total Assets	49.403	33.129	39.773		

### Liabilities (USD M)

	2011	2012	2013		
Accounts Payable	1.576	0.813	0.971		
Short Term Debt & Current Portion Of Long Term Debt	0.332	5.144	8.15		
Current Liabilities - Total	10.274	7.91	15.917		
Long Term Debt	8.048	15.5	7.35		
Other Liabilities	2.211	1.808	1.056		
Total Liabilities	24.661	27.968	39.633		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2011	2012	2013		
Minority Interest	0	0	0		
Preferred Stock	111.46	111.848	112.244		
Common Stock	0.007	0.007	0.001		
Treasury Stock	0	0	0		
Total Liabilities & Shareholders' Equity	49.403	33.129	39.773		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.38	-1.32	-1.39
31-Dec-2016	-1.23	-1.19	-1.23
31-Dec-2017	-1.38	-1.22	-1.38

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0	-0.95	-26.48	25.73
31-Dec-2016	0	-0.7	-26.92	29.52
31-Dec-2017			-30.57	28.12

[Return to Table of Contents](#)




## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	5	7
Infectious disease	1	5	6
Cardiovascular disease	1	4	5
Inflammatory disease	1	3	4
Neoplasm	0	4	4
Musculoskeletal disease	1	2	3
Psychiatric disorder	0	3	3
Genitourinary disease	1	1	2
Immune disorder	0	2	2
Respiratory disease	1	1	2
Gastrointestinal disease	1	1	2
Injury	1	0	1
Hematological disease	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	3
Discovery	3
Discontinued	2
No Development Reported	15

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	1	0	0	0	1
Drug - CRADA	1	0	0	0	1
Drug - Screening/Evaluation	1	0	1	0	2
Drug - Development/Commercialization License	4	0	0	0	4

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Genitourinary disease	0	3
Infectious disease	0	1
Cardiovascular disease	0	1
Psychiatric disorder	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 3	0	1
Phase 2	0	1
Phase 1	0	11

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

[Return to Table of Contents](#)



Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

### PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	61	0	61
Endocrine disease	46	0	46
Gastrointestinal disease	72	0	72
Genitourinary disease	67	0	67
Growth disorder	11	0	11
Hematological disease	37	0	37
Degeneration	14	0	14
Andrology	23	0	23
Immune disorder	58	0	58
Psychiatric disorder	35	0	35
Musculoskeletal disease	31	0	31
Neoplasm	56	0	56
Ocular disease	18	0	18
Genetic disorder	20	0	20
Metabolic disorder	41	0	41
Mouth disease	1	0	1
Neurological disease	82	0	82
Nutritional disorder	16	0	16
Respiratory disease	36	0	36
Infectious disease	41	0	41
Injury	6	0	6
Toxicity and intoxication	12	0	12
Inflammatory disease	49	0	49

[Return to Table of Contents](#)



Fatigue	3	0	3
Otorhinolaryngological disease	3	0	3
Gynecology and obstetrics	24	0	24
Dermatological disease	32	0	32
Ulcer	5	0	5

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### CTP-499

<b>Drug Name</b>	CTP-499
<b>Key Synonyms</b>	
<b>Originator Company</b>	CoNCERT Pharmaceuticals Inc
<b>Active Companies</b>	GlaxoSmithKline plc, CoNCERT Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Renal disease
<b>Target-based Actions</b>	PDE inhibitor
<b>Other Actions</b>	Antioxidant agent, Anti-inflammatory, Fibrosuppressant, Renal system agent
<b>Technologies</b>	Oral formulation, Controlled release formulation, Small molecule therapeutic
<b>Last Change Date</b>	10-Dec-2014

### CTP-347

<b>Drug Name</b>	CTP-347
<b>Key Synonyms</b>	
<b>Originator Company</b>	CoNCERT Pharmaceuticals Inc
<b>Active Companies</b>	CoNCERT Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Hot flashes
<b>Target-based Actions</b>	
<b>Other Actions</b>	5-HT uptake inhibitor
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	09-Apr-2014

[Return to Table of Contents](#)



**CTP-354**

<b>Drug Name</b>	CTP-354
<b>Key Synonyms</b>	
<b>Originator Company</b>	CoNCERT Pharmaceuticals Inc
<b>Active Companies</b>	CoNCERT Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Neuropathic pain, Muscle hypertonia
<b>Target-based Actions</b>	GABA A receptor modulator
<b>Other Actions</b>	Anxiolytic, Analgesic
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	13-Nov-2014

**CTP-730**

<b>Drug Name</b>	CTP-730
<b>Key Synonyms</b>	
<b>Originator Company</b>	CoNCERT Pharmaceuticals Inc
<b>Active Companies</b>	CoNCERT Pharmaceuticals Inc, Celgene Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer, Anti-inflammatory, Unspecified drug target
<b>Technologies</b>	Oral formulation, Suspension, Small molecule therapeutic
<b>Last Change Date</b>	05-Jan-2015

[Return to Table of Contents](#)


**C-10068**

<b>Drug Name</b>	C-10068
<b>Key Synonyms</b>	
<b>Originator Company</b>	CoNCERT Pharmaceuticals Inc
<b>Active Companies</b>	Walter Reed Army Institute of Research, CoNCERT Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Epilepsy, Neuropathic pain, Brain injury
<b>Target-based Actions</b>	Opioid receptor sigma agonist 1
<b>Other Actions</b>	Neuroprotectant, Analgesic, Antidepressant, Anticonvulsant agent
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	15-May-2014

**deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals**

<b>Drug Name</b>	deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals
<b>Key Synonyms</b>	
<b>Originator Company</b>	CoNCERT Pharmaceuticals Inc
<b>Active Companies</b>	Therapeutics for Rare and Neglected Diseases, CoNCERT Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Schistosomiasis
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic, Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	04-Sep-2014

[Return to Table of Contents](#)

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals

Drug Name	deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cystic fibrosis, Chronic obstructive pulmonary disease
Target-based Actions	CFTR stimulator
Other Actions	
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	15-May-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

